Phenelzine as a stimulant drug antagonist: a preliminary report.
Phenelzine administration, monitored via a pharmacy-controlled program, was employed in 38 subjects over a 6-month period to prevent amphetamine-type drug abuse, in much the same manner as disulfiram programs are employed against alcohol abuse. Advantages of the program were apparent, with a majority of subjects abstaining during the enforced phenelzine trial. Subjects generally made use of this abstinent period to benefit from a variety of psychotherapeutic modes, and demonstrated enhanced job and school performance and improved marital relationships. Results based on subject and observer reports, reports from dispensing pharmacies, and random urinalyses for drugs were encouraging. However, the study was uncontrolled and observational, and thus results are merely suggestive at present. Potential dangers as well as benefits of administering phenelzine to such a population are discussed.
D000293:Adolescent; D000328:Adult; D000428:Alcohol Drinking; D000662:Amphetamines / Q000037:antagonists & inhibitors*; D001463:Barbiturates / Q000494:pharmacology; D004336:Drug Antagonism; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D003932:Heroin / Q000494:pharmacology; D006801:Humans; D008297:Male; D010624:Phenelzine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019966:Substance-Related Disorders / Q000188:drug therapy*
D000662:Amphetamines; D001463:Barbiturates; D003932:Heroin; D010624:Phenelzine